Latest Insider Transactions at Roivant Sciences Ltd. (ROIV)
This section provides a real-time view of insider transactions for Roivant Sciences Ltd. (ROIV). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Roivant Sciences Ltd. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Roivant Sciences Ltd.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 24
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
75,000
-4.34%
|
$1,650,000
$22.53 P/Share
|
|
Dec 24
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
117,848
+6.38%
|
$353,544
$3.85 P/Share
|
|
Dec 24
2025
|
Frank Torti President and Vant Chair |
SELL
Bona fide gift
|
Direct |
110,489
-0.8%
|
-
|
|
Dec 24
2025
|
Frank Torti President and Vant Chair |
SELL
Other acquisition or disposition
|
Direct |
64,891
-0.47%
|
$1,427,602
$22.47 P/Share
|
|
Dec 23
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
200,000
-11.04%
|
$4,400,000
$22.45 P/Share
|
|
Dec 23
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
313,841
+14.76%
|
$941,523
$3.85 P/Share
|
|
Dec 23
2025
|
Richard Pulik CFO |
SELL
Open market or private sale
|
Direct |
406,731
-39.12%
|
$8,948,082
$22.42 P/Share
|
|
Dec 23
2025
|
Richard Pulik CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
260,000
+28.69%
|
$780,000
$3.85 P/Share
|
|
Dec 23
2025
|
Frank Torti President and Vant Chair |
BUY
Grant, award, or other acquisition
|
Direct |
175,380
+1.25%
|
$3,858,360
$22.45 P/Share
|
|
Dec 20
2025
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,129
-0.55%
|
$46,838
$22.41 P/Share
|
|
Dec 17
2025
|
Mayukh Sukhatme President & CIO |
SELL
Other acquisition or disposition
|
Direct |
32,682
-0.17%
|
$751,686
$23.09 P/Share
|
|
Dec 17
2025
|
Mayukh Sukhatme President & CIO |
SELL
Open market or private sale
|
Direct |
26,831
-0.14%
|
$617,113
$23.09 P/Share
|
|
Dec 17
2025
|
Mayukh Sukhatme President & CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
59,513
+0.31%
|
$714,156
$12.68 P/Share
|
|
Dec 17
2025
|
Keith S Manchester |
SELL
Open market or private sale
|
Indirect |
777,332
-1.53%
|
$17,878,636
$23.08 P/Share
|
|
Dec 17
2025
|
Daniel Allen Gold |
SELL
Open market or private sale
|
Indirect |
777,332
-1.53%
|
$17,878,636
$23.08 P/Share
|
|
Dec 17
2025
|
Qvt Financial LP |
SELL
Open market or private sale
|
Indirect |
777,332
-1.53%
|
$17,878,636
$23.08 P/Share
|
|
Dec 16
2025
|
Keith S Manchester |
SELL
Open market or private sale
|
Indirect |
917,282
-2.57%
|
$21,097,486
$23.01 P/Share
|
|
Dec 16
2025
|
Daniel Allen Gold |
SELL
Open market or private sale
|
Indirect |
917,282
-2.57%
|
$21,097,486
$23.01 P/Share
|
|
Dec 16
2025
|
Qvt Financial LP |
SELL
Open market or private sale
|
Indirect |
917,282
-2.57%
|
$21,097,486
$23.01 P/Share
|
|
Dec 15
2025
|
Matthew Gline CEO |
SELL
Other acquisition or disposition
|
Direct |
2,130,659
-3.86%
|
$44,743,839
$21.68 P/Share
|
|
Dec 15
2025
|
Matthew Gline CEO |
SELL
Open market or private sale
|
Direct |
1,740,000
-3.06%
|
$36,540,000
$21.68 P/Share
|
|
Dec 15
2025
|
Matthew Gline CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,870,659
+6.18%
|
$34,835,931
$9.81 P/Share
|
|
Dec 15
2025
|
Vivek Ramaswamy > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
478,708
-1.4%
|
$10,531,576
$22.05 P/Share
|
|
Dec 15
2025
|
Vivek Ramaswamy > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
353,745
-1.03%
|
$7,782,390
$22.05 P/Share
|
|
Dec 15
2025
|
Vivek Ramaswamy > 10% Shareholder |
BUY
Exercise of conversion of derivative security
|
Direct |
832,453
+2.36%
|
$9,989,436
$12.68 P/Share
|
|
Dec 12
2025
|
Vivek Ramaswamy > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
2,696,866
-7.42%
|
$56,634,186
$21.96 P/Share
|
|
Dec 12
2025
|
Vivek Ramaswamy > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,975,858
-5.16%
|
$41,493,018
$21.96 P/Share
|
|
Dec 12
2025
|
Vivek Ramaswamy > 10% Shareholder |
BUY
Exercise of conversion of derivative security
|
Direct |
4,672,724
+10.87%
|
$56,072,688
$12.68 P/Share
|
|
Dec 11
2025
|
Vivek Ramaswamy > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
1,095,550
-3.15%
|
$23,006,550
$21.64 P/Share
|
|
Dec 11
2025
|
Vivek Ramaswamy > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
774,142
-2.18%
|
$16,256,982
$21.64 P/Share
|
|
Dec 11
2025
|
Vivek Ramaswamy > 10% Shareholder |
BUY
Exercise of conversion of derivative security
|
Direct |
1,869,691
+5.0%
|
$22,436,292
$12.68 P/Share
|
|
Dec 09
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
200,000
-11.78%
|
$4,000,000
$20.85 P/Share
|
|
Dec 09
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
200,000
+10.54%
|
$600,000
$3.85 P/Share
|
|
Nov 20
2025
|
Eric Venker President & Immunovant CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,051
-0.47%
|
$141,020
$20.27 P/Share
|
|
Nov 20
2025
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,235
-0.32%
|
$24,700
$20.27 P/Share
|
|
Nov 19
2025
|
Keith S Manchester |
SELL
Open market or private sale
|
Indirect |
1,300,000
-1.71%
|
$26,000,000
$20.21 P/Share
|
|
Nov 19
2025
|
Daniel Allen Gold |
SELL
Open market or private sale
|
Indirect |
1,300,000
-1.71%
|
$26,000,000
$20.21 P/Share
|
|
Nov 19
2025
|
Qvt Financial LP |
SELL
Open market or private sale
|
Indirect |
1,300,000
-1.71%
|
$26,000,000
$20.21 P/Share
|
|
Nov 17
2025
|
Vivek Ramaswamy > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
539,650
-1.58%
|
$10,793,000
$20.51 P/Share
|
|
Nov 14
2025
|
Vivek Ramaswamy > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,027,670
-2.92%
|
$20,553,400
$20.33 P/Share
|
|
Nov 13
2025
|
Vivek Ramaswamy > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
287,283
-0.81%
|
$5,745,660
$20.81 P/Share
|
|
Nov 07
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
200,000
-11.73%
|
$4,000,000
$20.22 P/Share
|
|
Nov 07
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
200,000
+10.5%
|
$600,000
$3.85 P/Share
|
|
Oct 20
2025
|
Ilan Oren |
SELL
Payment of exercise price or tax liability
|
Direct |
281
-0.24%
|
$4,777
$17.74 P/Share
|
|
Oct 20
2025
|
Ilan Oren |
BUY
Grant, award, or other acquisition
|
Direct |
1,507
+1.25%
|
-
|
|
Oct 20
2025
|
James C Momtazee |
SELL
Payment of exercise price or tax liability
|
Direct |
158
-0.15%
|
$2,686
$17.74 P/Share
|
|
Oct 20
2025
|
James C Momtazee |
BUY
Grant, award, or other acquisition
|
Direct |
789
+0.72%
|
-
|
|
Oct 20
2025
|
Epperly Melissa B, |
BUY
Grant, award, or other acquisition
|
Direct |
1,056
+1.82%
|
-
|
|
Oct 17
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
118,418
-7.29%
|
$2,013,106
$17.06 P/Share
|
|
Oct 17
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
118,418
+6.8%
|
$1,776,270
$15.85 P/Share
|